OncoRedox
Point-of-care Testing Device for Cancer Detection
Health Tech & Life Sciences
Private
Company Overview
Snapshot
Founded in August 2022 by Gal Meister, OncoRedox operates with 1-10 employees. The company has secured funding across one round from one investor, Peregrine Ventures, to advance its point-of-care cancer detection technology.
Business overview
OncoRedox is a Health Tech & Life Sciences company developing a point-of-care testing device for cancer detection. Its core technology utilizes 'Redox-omics' analysis of urine samples, employing biochemical electrodes to detect redox metabolic signatures through an AI analysis model. The company operates within the medical devices and diagnostics devices sectors, targeting the healthcare and life sciences industry, specifically healthcare providers.
Log in to access full profile ›Company Intelligence Q&A
- What is OncoRedox's primary focus?
- OncoRedox focuses on developing a point-of-care testing device for cancer detection, utilizing 'Redox-omics' analysis of urine samples.
- When was OncoRedox founded and by whom?
- OncoRedox was founded in August 2022 by Gal Meister.
- What technology underpins OncoRedox's cancer detection device?
- The technology is based on biochemical electrodes that detect redox metabolic signatures, which are then analyzed using an AI model.
- In which sectors does OncoRedox primarily operate?
- OncoRedox operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Diagnostics Devices.